A New Drug Switches On Its Receptor Through Quantum Vibration-Assisted Tunneling

Summary

A quantum-chemical modeling study extends inelastic electron tunneling spectroscopy (IETS) from olfactory receptors to the mammalian serotonin receptor (5-HT2A). It finds that several serotonin agonists, including LSD and DOI, share a common vibrational peak near 1500 cm⁻¹ whose intensity scales with the drug's potency, suggesting that receptor activation may depend not only on a molecule's shape but also on its vibration. To test this, the authors propose deuterated versions of the LSD analogue DAM-57, which would alter the vibration while leaving the shape almost untouched. If validated, this mechanism could open a new path to computer-based potency prediction in drug discovery.

Study at a glance

Abstract

Published in Scientific Reports (Nature Portfolio), this study extends inelastic electron tunneling spectroscopy (IETS)—originally proposed as a model for olfactory receptor activation—to the mammalian serotonin receptor (5-HT2A) through quantum-chemical modeling. It finds that several serotonin agonists, including LSD and DOI, share a common vibrational peak near 1500 cm⁻¹ whose intensity scales with the drug's potency, suggesting that the key to receptor activation may be not only a molecule's shape but its vibration. As a way to test this, it proposes deuterated versions of the LSD analogue DAM-57. The design—leaving the molecular shape almost untouched while altering only the vibration to check for a change in potency—could open a new path to computer-based potency prediction in drug discovery. [Quantum Biology Society] A large share of modern medicines target G protein-coupled receptors (GPCRs) on the cell surface. Yet how a drug (an agonist) switches such a receptor on—how it activates it—remains a fundamental question of pharmacology and drug design that is still not fully understood. The lock-and-key model, long used as the standard, explains a molecule's shape and binding but has been limited in predicting how strongly a drug acts (its potency). At the serotonin receptor, for instance, the two molecules DOI and DOB have almost the same binding affinity (docking) yet differ greatly in potency. Something beyond shape is clearly at work. A 2015 paper in the Nature Portfolio journal Scientific Reports, "Neuroreceptor Activation by Vibration-Assisted Tunneling," proposes a quantum-mechanical answer to this question. Ross D. Hoehn, David Nichols, and Sabre Kais of Purdue University, together with Hartmut Neven of Google, extended to the serotonin receptor a vibrational theory originally put forward to explain olfaction (the recognition of odorant molecules). The core idea is that a receptor is activated by reading not only the shape of the molecule it binds but also that molecule's characteristic vibration. ■ Beyond Shape: Vibration Opens a Channel for the Electron The roots of this theory lie in olfaction. The vibrational theory—that odor receptors sense the vibrations of odorant molecules—was once dismissed for lacking a clear mechanism, but it drew renewed attention when Luca Turin and others refined it into a physical mechanism resembling inelastic electron tunneling spectroscopy (IETS). Mapped onto a receptor, the mechanism runs as follows. The receptor's binding site is viewed as a single tunneling junction that an electron must cross, with specific amino acid residues forming the two walls of the junction as the electron donor and the electron acceptor. An electron cannot easily cross this gap on its own; but if it can hand off a packet of energy of exactly the right size to match a vibrational mode of the bound agonist, an inelastic channel opens through which the electron passes while exciting that vibration. The researchers propose that this very electron transfer is the trigger that switches the receptor on. The energy that drives the electron, they suggest, could be supplied by an ionic cofactor such as a calcium ion. The upshot is a picture in which each agonist's distinctive vibrational fingerprint, quite apart from its shape, takes part in receptor activation. ■ A Shared Peak at 1500 cm⁻¹, Marching in Step With Potency Using density functional theory (DFT) and normal-mode analysis, the researchers calculated the tunneling spectra of several 5-HT2A agonists. The subjects were hallucinogenic compounds including LSD and DOI, phenethylamines of the 2C-X class and amphetamines of the DOX class—many of them first characterized by the chemist Alexander Shulgin. The calculations showed that these agonists shared a common peak in one particular vibrational band, at 1500 cm⁻¹. More striking still, the intensity of this peak (the integral over the 1500 ± 35 cm⁻¹ range) tracked each drug's potency. Taking the most potent compound, LSD, as the reference, the peak intensity was roughly proportional to the inverse of the EC50—that is, to potency. The motions contributing to this band were stretching of the amide methyl hydrogens, stretching of the phenyl and indole hydrogens, and bending of the tertiary-amine methyl hydrogens. The potency difference between DOI and DOB—indistinguishable by shape alone—could, from this vibrational standpoint, finally begin to find an explanation. ■ Testing It With Deuterium: The Proposed DAM-57 Experiment To turn the theory into an experiment, the tool the researchers chose was deuterium. The target molecule was DAM-57 (lysergic acid dimethylamide), an analogue of LSD that carries a methyl group in place of LSD's flexible ethyl amide and is therefore far less potent. Deuterium is chemically almost identical to ordinary hydrogen, so it barely affects a molecule's shape or binding, but its mass is twice as great, which shifts vibrational frequencies. Substituting deuterium at specific positions therefore makes it possible to selectively lower the 1500 cm⁻¹ vibrational peak while leaving the shape intact. The researchers' prediction is clear: deuterating the amide side chain to deplete this peak should also reduce the compound's potency at the receptor. In the calculations, one substituted form (DAM-57-iv) showed its peak intensity cut to about one-third of the original and its tunneling probability density to roughly one-tenth, pointing to a steep drop in potency. Since binding and kinetic isotope effects alone rarely change potency by more than about 10%, a deuterium substitution that produces a much larger change would be strong evidence for the vibrational mechanism—a falsifiable prediction, in other words. ■ Significance, and a Note of Caution If this work is validated, it would not only supply a quantum-mechanical explanation for the biological phenomenon of receptor activation but could also become a new tool for predicting, by computer, the potency and activity of drugs that docking alone has struggled to capture. Its potential lies in broadening the perspective of drug design from shape-matching to vibration-reading. There are, however, clear reasons for caution. This is a computational and theoretical study, and the correlation between peak intensity and potency is a broad trend observed in a limited number of molecules. Above all, the olfactory vibrational theory at the root of this approach remains contested. In odor perception, shape-based explanations are the mainstream, and experiments on whether humans can distinguish deuterated molecules by smell have yielded conflicting results. The DAM-57 experiment the authors propose was, as of this paper, still an untested prediction. This study is therefore best read not as an established mechanism but as a provocative and testable hypothesis equipped with a clear path to verification. In treating the activation of neurotransmitter and drug receptors through quantum vibration-assisted tunneling—unlike the existing olfaction (odorant-vibration) entries—this paper adds a pharmacological perspective that the archive had not previously held. #QuantumBiology #QuantumTunneling #Neuroscience #SerotoninReceptor #DrugDiscovery #VibrationalTheory #Olfaction #GPCR #LSD #DeuteriumSubstitution https://www.nature.com/articles/srep09990